Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma

Abstract

Non-alcoholic fatty liver disease (NAFLD) and its advanced complication, non-alcoholic steatohepatitis (NASH), have become leading causes of hepatocellular carcinoma (HCC) worldwide. In this review, we discuss the role of metabolic, gut microbial, immune and endocrine mediators which promote the progression of NAFLD to HCC. In particular, this progression involves multiple hits resulting from lipotoxicity, oxidative stress, inhibition of hepatic autophagy and inflammation. Furthermore, dysbiosis in the gut associated with obesity also promotes HCC via induction of proinflammatory cytokines and Toll like receptor signalling as well as altered bile metabolism. Additionally, compromised T-cell function and impaired hepatic hormonal action promote the development of NASH-associated HCC. Lastly, we discuss the current challenges involved in the diagnosis and treatment of NAFLD/NASH-associated HCC.

Keywords

Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis / hepatocellular carcinoma / Gut microbiome / dysbiosis / autophagy / ER-stress / ROS / TNFα / TLR-9 / TLR-4 / hyperinsulinemia

References

[1] Akinyemiju T,Ahmed M,Alemayohu MA.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015..JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[2] Blonski W,Forde KA.Non-viral causes of hepatocellular carcinoma..World J Gastroenterol2010;16:3603-15 PMCID:PMC2915420

[3] Bertot LC.Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease..Expert Rev Gastroenterol Hepatol2019;13:179-87

[4] Swinburn BA,Hall KD,Finegood DT.The global obesity pandemic: shaped by global drivers and local environments..Lancet2011;378:804-14

[5] Younossi Z,Marietti M,Henry L.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention..Nat Rev Gastroenterol Hepatol2018;15:11-20

[6] Bhaskaran K,Forbes H,Leon DA.Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults..Lancet2014;384:755-65 PMCID:PMC4151483

[7] Milic S,Stimac D.Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations..World J Gastroenterol2014;20:9330-7 PMCID:PMC4110564

[8] Fan JG,Wong VW.New trends on obesity and NAFLD in Asia..J Hepatol2017;67:862-73

[9] Petrucciani N.Molecular pathways between obesity, non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)..Hepatobiliary Surg Nutr2019;8:395-7 PMCID:PMC6700016

[10] Xia MF,Gao X.NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment..Front Pharmacol2019;10:877 PMCID:PMC6691129

[11] Masarone M,Aglitti A,Caruso R.Liver biopsy in type 2 diabetes mellitus: steatohepatitis represents the sole feature of liver damage..PLoS One2017;12:e0178473 PMCID:PMC5453539

[12] Bril F.Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action..Diabetes Care2017;40:419-30

[13] Mantovani A.Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease..Ann Transl Med2017;5:270 PMCID:PMC5515814

[14] Agosti P,Mazzocca A.Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment..Biochim Biophys Acta Mol Basis Dis2018;1864:607-17

[15] Yang JD,Mara KC,Allen AM.Diabetes is associated with increased risk of hepatocellular carcinoma in cirrhosis patients with nonalcoholic fatty liver disease..Hepatology2019;Epub ahead of print. doi: 10.1002/hep.30858

[16] Margini C.The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment..Liver Int2016;36:317-24

[17] Younossi Z,Ong JP,Bugianesi E.Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates..Clin Gastroenterol Hepatol2019;17:748-55.e3

[18] Reig M,Man NK,Victor D.Should patients with NAFLD/NASH be surveyed for HCC?.Transplantation2019;103:39-44

[19] Sadler EM,Bhat M,Greig PD.Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma..Transplantation2018;102:640-7

[20] Olofson AM,Chang M.Steatohepatitic variant of hepatocellular carcinoma: a focused review..Gastroenterology Res2018;11:391-6 PMCID:PMC6306112

[21] Kanwal F,Mapakshi S,Chayanupatkul M.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease..Gastroenterology2018;155:1828-37.e2 PMCID:PMC6279617

[22] Estes C,Arias-Loste MT,Bellentani S.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030..J Hepatol2018;69:896-904

[23] Uygun A.Is that possible to stop or cease the NASH to turn into HCC?.J Gastrointest Cancer2017;48:250-5

[24] Yopp AC.Non-alcoholic steatohepatitis-related hepatocellular carcinoma: a growing epidemic?.Dig Dis2015;33:642-7

[25] Weinmann A,Koch S,Duber C.Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma..BMC Cancer2015;15:210 PMCID:PMC4407550

[26] Oda K,Mawatari S.Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies..Clin J Gastroenterol2015;8:1-9

[27] Page JM.NASH and HCC..Clin Liver Dis2009;13:631-47

[28] Zen Y,Tsuneyama K,Araki I.Hepatocellular carcinoma arising in non-alcoholic steatohepatitis..Pathol Int2001;51:127-31

[29] Gawrieh S,Miller E,deLemos A.Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study..Aliment Pharmacol Ther2019;50:809-21

[30] Grohmann M,Dodd GT,Ooi GJ.Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC..Cell2018;175:1289-306.e20 PMCID:PMC6242467

[31] Younossi ZM,Henry L,Mishra A.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009..Hepatology2015;62:1723-30

[32] Piscaglia F,Barchetti A,Marinelli S.Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study..Hepatology2016;63:827-38

[33] Yasui K,Komorizono Y,Arii S.Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma..Clin Gastroenterol Hepatol2011;9:428-33

[34] Ertle J,Sowa JP,Herzer K.Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis..Int J Cancer2011;128:2436-43

[35] Chen K,Jia X,Ma Z.Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans..Biochim Biophys Acta Rev Cancer2019;1871:117-25

[36] Anstee QM.The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2..Semin Liver Dis2015;35:270-90

[37] Buzzetti E,Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)..Metabolism2016;65:1038-48

[38] Bessone F,Roma MG.Molecular pathways of nonalcoholic fatty liver disease development and progression..Cell Mol Life Sci2019;76:99-128

[39] Spahis S,Borys JM.Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis..Antioxid Redox Signal2017;26:519-41

[40] Zhang XQ,Yu CH,Li YM.Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease..World J Gastroenterol2014;20:1768-76 PMCID:PMC3930975

[41] Gadd VL,Powell EE,Winterford C.The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease..Hepatology2014;59:1393-405

[42] Krenkel O,Govaere O,Mossanen JC.Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis..Hepatology2018;67:1270-83

[43] Sookoian S.Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease..Hepatology2011;53:1883-94

[44] Singal AG,Yopp AC,Marrero JA.The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis..Am J Gastroenterol2014;109:325-34 PMCID:PMC5610907

[45] Liu YL,Leathart JB,Burt AD.Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma..J Hepatol2014;61:75-81

[46] Kozlitina J,Stender S,Zhou HH.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease..Nat Genet2014;46:352-6 PMCID:PMC3969786

[47] Chen LZ,Xin YN,Xuan SY.TM6SF2 E167K variant, a novel genetic susceptibility variant, contributing to nonalcoholic fatty liver disease..J Clin Transl Hepatol2015;3:265-70 PMCID:PMC4721894

[48] Donati B,Romeo S,McCain M.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals..Sci Rep2017;7:4492 PMCID:PMC5495751

[49] Schulze K,Letouze E,Calderaro J.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets..Nat Genet2015;47:505-11 PMCID:PMC4587544

[50] Tryndyak VP,Muskhelishvili L,Ross SA.Coupling global methylation and gene expression profiles reveal key pathophysiological events in liver injury induced by a methyl-deficient diet..Mol Nutr Food Res2011;55:411-8

[51] Liu F,Chang H,Lu J.Identification of hepatocellular carcinoma-associated hub genes and pathways by integrated microarray analysis..Tumori2015;101:206-14

[52] Erstad DJ,Tanabe KK.Molecular signatures in hepatocellular carcinoma: a step toward rationally designed cancer therapy..Cancer2018;124:3084-104

[53] de Conti A,Tryndyak V,Moreno FS.MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis..Oncotarget2017;8:88517-28 PMCID:PMC5687623

[54] Xu Z,Cao H,Cigliano A.Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway..Exp Mol Med2018;50:e417 PMCID:PMC5992985

[55] Tessitore A,Del Vecchio F,Verzella D.MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice..BMC Cancer2016;16:3 PMCID:PMC4700747

[56] Takakura K,Nakano M,Torisu Y.Recent insights into the multiple pathways driving non-alcoholic steatohepatitis-derived hepatocellular carcinoma..Front Oncol2019;9:762 PMCID:PMC6700399

[57] Anstee QM,Kotsiliti E,Heikenwalder M.From NASH to HCC: current concepts and future challenges..Nat Rev Gastroenterol Hepatol2019;16:411-28

[58] Grattagliano I,Bernardo TC,Wang DQ.Role of mitochondria in nonalcoholic fatty liver disease - from origin to propagation..Clin Biochem2012;45:610-8

[59] Donnelly KL,Schwarzenberg SJ,Boldt MD.Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease..J Clin Invest2005;115:1343-51 PMCID:PMC1087172

[60] Nakagawa H,Kawamura S,Fujiwara N.Lipid metabolic reprogramming in hepatocellular carcinoma..Cancers (Basel)2018;10:E447 PMCID:PMC6265967

[61] Hirsova P,Gores GJ.Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis..J Lipid Res2016;57:1758-70 PMCID:PMC5036373

[62] Garcia-Ruiz C.Mitochondrial oxidative stress and antioxidants balance in fatty liver disease..Hepatol Commun2018;2:1425-39 PMCID:PMC6287487

[63] Masarone M,Dallio M,Aglitti A.Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease..Oxid Med Cell Longev2018;2018:9547613 PMCID:PMC6016172

[64] Fu Y.Oxidative stress and hepatocarcinogenesis..Hepatoma Res2018;4: PMCID:PMC6370311

[65] Nishida N,Hagiwara S,Kitano M.Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease..J Gastroenterol Hepatol2016;31:1646-53

[66] Song MJ.The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease..Pharmacol Ther2019;203:107401 PMCID:PMC6848795

[67] Nakagawa H,Taniguchi K,Dhar D.ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development..Cancer Cell2014;26:331-43 PMCID:PMC4165611

[68] Wu WKK,Chan MTV.Autophagy, NAFLD and NAFLD-related HCC..Adv Exp Med Biol2018;1061:127-38

[69] Tian Y,Qiu W,Zhang Z.ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy..Nat Commun2019;10:3391 PMCID:PMC6662851

[70] Ichimura Y,Sou YS,Hasegawa J.Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy..Mol Cell2013;51:618-31

[71] Sinha RA,Zhou J,Farah BL.Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling..Autophagy2015;11:1341-57 PMCID:PMC4590606

[72] Sun K,Jing Y,Chen X.Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-kappaB-IL1alpha/beta-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis..Cancer Lett2017;388:198-207

[73] Kanno M,Honda M,Takatori H.Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis..J Gastroenterol2019;54:549-57

[74] Arendt BM,Pettinelli P,Ma DWL.Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease..Nutrition2019;62:100-7

[75] Torres-Mena JE,Sanchez-Rodriguez R,Del Pozo-Yauner L.Aldo-Keto reductases as early biomarkers of hepatocellular carcinoma: a comparison between animal models and human HCC..Dig Dis Sci2018;63:934-44

[76] Nikolaou N,Marchand L,Dempster NJ.AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease..Metabolism2019;99:67-80 PMCID:PMC6744372

[77] Marra F.Lipotoxicity and the gut-liver axis in NASH pathogenesis..J Hepatol2018;68:280-95

[78] Iannucci LF,Singh BK,Kaddai VA.Short chain fatty acids induce UCP2-mediated autophagy in hepatic cells..Biochem Biophys Res Commun2016;480:461-7

[79] Koopman N,Nieuwdorp M.Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease..Aliment Pharmacol Ther2019;50:628-39

[80] Jandhyala SM,Subramanyam C,Sasikala M.Role of the normal gut microbiota..World J Gastroenterol2015;21:8787-803 PMCID:PMC4528021

[81] Mouries J,Silvestri A,Sorribas M.Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development..J Hepatol2019;71:1216-28 PMCID:PMC6880766

[82] Liu Q,Chen L,Du S.Role and effective therapeutic target of gut microbiota in NAFLD/NASH..Exp Ther Med2019;18:1935-44 PMCID:PMC6676192

[83] Kim HN,Cheong HS,Kim HL.Gut microbiota and risk of persistent nonalcoholic fatty liver diseases..J Clin Med2019;8:E1089 PMCID:PMC6722749

[84] Jasirwan COM,Hasan I,Gani RA.The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms..Biosci Microbiota Food Health2019;38:81-8 PMCID:PMC6663510

[85] Leung C,Furness JB.The role of the gut microbiota in NAFLD..Nat Rev Gastroenterol Hepatol2016;13:412-25

[86] Ezzaidi N,Coker OO.New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer..Cancer Lett2019;459:186-91

[87] Yoshimoto S,Atarashi K,Sato S.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome..Nature2013;499:97-101

[88] Dapito DH,Gwak GY,Jang MK.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4..Cancer Cell2012;21:504-16 PMCID:PMC3332000

[89] Chu H,Schnabl B.Gut microbiota, fatty liver disease, and hepatocellular carcinoma..Liver Res2018;2:43-51 PMCID:PMC6223644

[90] Nguyen J,Smoot K,Zhao C.Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis..Oncotarget2018;9:29495-507 PMCID:PMC6047684

[91] Liu Y,Tohme S,Fu Y.Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9..J Hepatol2015;63:114-21 PMCID:PMC4475488

[92] Brandi G,Candela M,Bellentani S.Microbiota, NASH, HCC and the potential role of probiotics..Carcinogenesis2017;38:231-40

[93] Takahashi S,Fukami T,Yagai T.Role of farnesoid X receptor and bile acids in hepatic tumor development..Hepatol Commun2018;2:1567-82 PMCID:PMC6287584

[94] He G.NF-kappa B and STAT3 - key players in liver inflammation and cancer..Cell Res2011;21:159-68 PMCID:PMC3193410

[95] Park EJ,Yu GY,Ali SR.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression..Cell2010;140:197-208 PMCID:PMC2836922

[96] Min HK,Verdianelli A,Patel V.Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease..Am J Physiol Gastrointest Liver Physiol2015;308:G794-803 PMCID:PMC4421014

[97] Widjaja AA,Adami E,Dong J.Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis..Gastroenterology2019;157:777-92.e14

[98] Zheng H,Han J,Chen C.TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling..Sci Rep2016;6:37070 PMCID:PMC5128793

[99] Gomes AL,Buren S,Yilmaz M.Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma..Cancer Cell2016;30:161-75

[100] Syn WK,Liaskou E,Agboola KM.Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis..Hepatology2011;53:106-15 PMCID:PMC3025083

[101] Chung SI,Ju HL,Kim DY.Hepatic expression of sonic hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model..J Hepatol2016;64:618-27

[102] Chen J,Su X.Immunomodulatory TGF-beta signaling in hepatocellular carcinoma..Trends Mol Med2019;25:1010-23

[103] Yang L,Song J,Liu C.Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice..Hepatology2014;59:483-95 PMCID:PMC3946696

[104] Jin Z,Lin D,Song Y.IL-33 released in the liver inhibits tumor growth via promotion of CD4(+) and CD8(+) T cell responses in hepatocellular carcinoma..J Immunol2018;201:3770-9

[105] Ma C,Eggert T,Kleiner DE.NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis..Nature2016;531:253-7 PMCID:PMC4786464

[106] Malehmir M,Gallage S,Inverso D.Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer..Nat Med2019;25:641-55

[107] de Oliveira S,Graves AL,Korte BG.Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish..J Hepatol2019;70:710-21 PMCID:PMC6436385

[108] Bril F,Orsak B,Webb A.Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis..Hepatology2014;59:2178-87

[109] De Minicis S,Rychlicki C,Saccomanno S.HCC development is associated to peripheral insulin resistance in a mouse model of NASH..PLoS One2014;9:e97136 PMCID:PMC4031080

[110] Kudo Y,Tateishi K,Yamamoto S.Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway..J Hepatol2011;55:1400-8

[111] Jeong SH,Kim MC,Lee JH.Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer..J Clin Invest2018;128:1010-25 PMCID:PMC5824861

[112] Chettouh H,Fartoux L,Desbois-Mouthon C.Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma..Liver Int2015;35:2203-17

[113] Polyzos SA,Kountouras J,Vasiloglou MF.Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis..Diabetologia2016;59:30-43

[114] Jiang N,Sun Q.Leptin signaling molecular actions and drug target in hepatocellular carcinoma..Drug Des Devel Ther2014;8:2295-302 PMCID:PMC4238752

[115] Stefanou N,Furukawa Y,Tsezou A.Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase..BMC Cancer2010;10:442 PMCID:PMC2931493

[116] Bruinstroop E,Cao Y,Chandran K.Low-dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD..J Clin Endocrinol Metab2018;103:2698-706

[117] Pinter M,Hucke F,Bucsics T.The impact of thyroid hormones on patients with hepatocellular carcinoma..PLoS One2017;12:e0181878 PMCID:PMC5542594

[118] Lonardo A,Mantovani A,Lugari S.Pathogenesis of hypothyroidism-induced NAFLD: evidence for a distinct disease entity?.Dig Liver Dis2019;51:462-70

[119] Sinha RA,Singh BK.Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists..Thyroid2019;29:1173-91 PMCID:PMC6850905

[120] Ali MA,Abdel-Wahab R,Hassan M.Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?.Onco Targets Ther2017;10:1403-12 PMCID:PMC5344425

[121] Wu EM,Hernandez BY,Jia W.Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation..Hepatoma Res2018;4: PMCID:PMC6347119

[122] Bosch FX,Diaz M.Primary liver cancer: worldwide incidence and trends..Gastroenterology2004;127:S5-16

[123] Gan L,Farrell GC.Mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly..Curr Gerontol Geriatr Res2011;2011:831536 PMCID:PMC3171768

[124] Hashimoto E.Prevalence, gender, ethnic variations, and prognosis of NASH..J Gastroenterol.2011;46 Suppl 1:63-9

[125] Iyer JK,Kaul A,Kaul R.Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis..World J Gastroenterol2017;23:6802-16 PMCID:PMC5645614

[126] Kettner NM,Finegold MJ,Sreekumar A.Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis..Cancer Cell2016;30:909-24 PMCID:PMC5695235